GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc Buys 50,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc bought 50,000 shares of the stock in a transaction on Monday, May 13th. The stock was purchased at an average price of $23.31 per share, for a total transaction of $1,165,500.00. Following the completion of the purchase, the director now directly owns 2,753,509 shares in the company, valued at $64,184,294.79. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Casdin Capital, Llc also recently made the following trade(s):

• On Monday, March 4th, Casdin Capital, Llc purchased 40,000 shares of GeneDx stock. The shares were acquired at an average price of $8.74 per share, for a total transaction of $349,600.00.

GeneDx Stock Up 8.6 %

Shares of WGS stock traded up $1.82 during midday trading on Thursday, reaching $22.98. 159,422 shares of the stock were exchanged, compared to its average volume of 388,572. The firm has a market cap of $600.24 million, a PE ratio of -4.44 and a beta of 2.17. The company has a current ratio of 3.22, a quick ratio of 2.99 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $12.34 and its two-hundred day moving average is $6.50. GeneDx Holdings Corp. has a 1 year low of $1.16 and a 1 year high of $23.79.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. GeneDx had a negative return on equity of 36.23% and a negative net margin of 60.86%. The business had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. On average, equities research analysts predict that GeneDx Holdings Corp. will post -2.02 EPS for the current year.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently bought and sold shares of WGS. Oracle Investment Management Inc. lifted its stake in shares of GeneDx by 531.7% in the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after buying an additional 948,253 shares in the last quarter. Vanguard Group Inc. increased its holdings in GeneDx by 4.2% in the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock worth $6,460,000 after buying an additional 28,678 shares in the last quarter. Gagnon Securities LLC grew its stake in shares of GeneDx by 59.3% in the first quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock worth $5,079,000 after acquiring an additional 207,027 shares during the period. HighTower Advisors LLC raised its holdings in shares of GeneDx by 14.1% during the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after purchasing an additional 29,361 shares during the last quarter. Finally, Gagnon Advisors LLC lifted its position in GeneDx by 41.6% during the first quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after purchasing an additional 62,059 shares during the period. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on WGS shares. The Goldman Sachs Group boosted their target price on GeneDx to $11.00 and gave the company a “neutral” rating in a research note on Monday, April 15th. TD Cowen raised their price target on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Finally, BTIG Research boosted their price objective on shares of GeneDx from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.